Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Core Insights - Tevogen Bio Holdings Inc. estimates the risk-adjusted net present value (rNPV) of its product TVGN-489 to be between $9 billion and $11 billion, targeting treatment for SARS-CoV-2 and Long-COVID in high-risk patients [1][3] Clinical Trial Findings - In a Phase I proof-of-concept trial, two cancer patients received TVGN-489 and were able to proceed to stem cell transplants shortly after treatment, with no complications from COVID-19 observed [2] - High-risk ambulatory patients showed significant viral elimination, with ≥88% of patients achieving viral clearance by Day 4 and >99% by Day 14 [7] - No disease progression or recurrent COVID-19 cases were reported in the treatment arm during a six-month follow-up [7] Revenue Projections - Tevogen's cumulative revenue projections for TVGN-489 over five years indicate a strong market potential, with the rNPV reflecting only U.S. revenue potential and not the broader ExacTcell™ technology platform [3][4] Future Plans - The company plans to provide ongoing updates regarding the valuation of its internally developed assets, including product pipeline developments [4]